NewLimit raises $130 million Series B led by Kleiner Perkins alongside NFDG, Khosla Ventures, Human Capital and others

NewLimit is developing medicines to extend human healthspan through epigenetic reprogramming

We founded NewLimit to develop medicines that add healthy years to each human life. Initially, we thought it would take many years to show progress toward this goal. We’re proud that our team achieved this milestone faster than we expected. Based on these results, we’ve raised a $130 million Series B led by Kleiner Perkins alongside new investors Nat Friedman/Daniel Gross, Khosla Ventures, Human Capital, and Valor Equity Partners — joined by existing investors Dimension, Founders Fund, and Brian Armstrong. We also raised from some of the best angels who have supported the company over the first two years including John and Patrick Collison, Fred Ehrsam, Elad Gil, Joshua Kushner, Joe Lonsdale, and Garry Tan.

NewLimit is building medicines to treat aging, the meta driver of nearly every major human disease. Once thought to be irreversible, the emerging science of epigenetic reprogramming has shown that aging is in fact malleable. This presents a therapeutic opportunity that is 100X larger than any biotech product that has come before.

NewLimit’s approach is conceptually straightforward – we’ve built technology to run the largest experiments in the field, and we use the resulting data to train frontier AI models that ensure we only test the most promising potential medicines. Our bet is that this combination of AI and scaled genomics can unlock medicines that give each of us more healthy years. We have a stepwise, capital efficient plan to get there.

We're deeply appreciative of investors who share our vision that addressing aging biology represents one of the most consequential projects of humanity. We hope our progress will help inspire broader interest and investment in aging therapeutics.

Our story is just getting started. If you want to be a part of it, join us at newlimit.com/careers.